Contemporary Pharmacotherapy for OAB 2021: Monotherapy and Combined Pharmacotherapy to Optimize Treatment (2021)

CME Available: https://auau.auanet.org/node/31460

ACKNOWLEDGEMENTS

Support provided by independent educational grants from AbbVie, Astellas, Medtronic, Urovant Sciences, Inc.

At the conclusion of the activity, participants will be able to:

1. Define the similarities and differences between the various oral pharmacotherapies for overactive bladder (OAB).

2. Review the principles of physiology and pharmacotherapy for currently available agents, including the anti-muscarinics and beta-3 agonists and combination therapy.

3. Express the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies.

4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents.

5. Discuss potential future pharmacological pathways and therapies for OAB.